For instance, a recent phase II clinical trial combined PD-L1 inhibitors with doxorubicin-based chemotherapy, demonstrating a synergistic effect that improved response rates and overcame chemoresistance in osteosarcoma patients (108). This evidence concerns the gene CD274 and osteosarcoma.